健康管理防治宫颈持续性高危型HPV感染的研究

目的探讨健康管理防治持续性（HPV感染1年以上）高危型HPV感染的疗效及价值。方法选择2008年1月至2011年4月在番禺疗养院、番禺区中心医院及番禺市桥医院体检发现持续性高危型HPV感染患者90例为研究对象。随机分为治疗组47例,采用健康管理方法（健康体检、生活指导、行为干预、定期进行健康讲座、建立健康管理档案）;对照组43例,不用药物,定期随访复查。两组患者分别于6个月及12个月后返诊复查第二代基因捕获杂交方法（HC-Ⅱ）检测宫颈高危型HPV-DNA,并联合液基细胞学（TCT）及阴道镜检查,必要时行宫颈活检。结果 6个月及12个月后复查HCⅡ及TCT,治疗组HPV转阴率及显效率均高于对照组,但差异无统计学意义（P〉0.05）;两组患者6个月HPV检测RLU/CO比值（负荷量）比较,差异无统计学意义（P〉0.05）;两组患者12个月HPV检测RLU/CO比值比较,治疗组低于对照组,差异有统计学意义（P〈0.05）。结论长期系统的健康管理可提高患者免疫力,促使女性自愿采取有利于健康的行为和生活方式,有效降低HPV比值,在防治持续性高危型HPV感染方面具有一定的临床价值。

The Rsearch of Health Management for Prevention and Treatment of Cervical Persistent High-risk HPV Infection

Objective To investigate the efficacy and value of health management for prevention and treatment of persistent high-risk HPV （HR-HPV） infection. Methods 90 patients with persistent HR-HPV infection were randomly divided into treatment group （47 cases） and control group （43 cases）. The treatment group received health management （health examination, life instruction, behavioral interventions, regular health lecture and establishing health management files）. The control group received the regular follow-up alone without any drugs. Six and twelve months later, all the patients received hybrid capture Ⅱ （HC II） and thinprep cytologic test （TCT）, colposcopy, cervical biopsy when necessary. Results Six and twelve months later, negative and effective rates of HPV in the treatment group were higher than those in the control group, without statistical significance between them （P 0.05）. Six months later, there was no statistical significance between two goups in RLU/CO ratio of HPV （P 0.05）. Twelve months later, the RLU/CO ratio of HPV in treatment group was lower than that in the control group, and there was statistical significance between two groups （P 0.05）. Conclusions The long and systematic health management can improve patients＇ immune system, enable women volunteers to take the behavior and lifestyle that is conducive to health, effectively reduce the ratio of HPV. Systematic health management has invariably clinical values in preventing and treating persistent HR-HPV infection.